Standard BioTools Inc. LAB 深 滬
等待開盤 04-09 09:30:00 美东时间
0.9368
+0.012
+1.28%
華盛通- 最 高0.95
- 今 開0.93
- 成交量 145.54万股
- 最 低 0.9003
- 昨 收 0.925
- 總市值 3.65亿
- 52周最高 1.72
- 市盈率 靜 --
- 換手率 0.37%
- 52周最低 0.8702
- 委 比 -65.45%
- 總股本 3.90亿
- 歷史最高 49.455
- 量 比 0.73
- 振 幅 5.37%
- 歷史最低 0.8702
- 每 手 1
- 風險率 0.17%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Standard BioTools Q4 Earnings Report: What Investors Need to Know
Standard BioTools (NASDAQ:LAB) released its Q4 earnings on Tuesday, February 24...
02-25 05:17
Earnings Scheduled For February 24, 2026
Companies Reporting Before The Bell • China Yuchai Intl (NYSE:CYD) is expected ...
02-24 19:11
Preview: Standard BioTools's Earnings
Standard BioTools (NASDAQ:LAB) will release its quarterly earnings report on Tu...
02-24 02:02
Standard BioTools Inc. hat eine Aktualisierung ihres Finanzkalenders veröffentlicht
Standard BioTools Inc. hat eine Aktualisierung ihres Finanzkalenders veröffentlicht Standard BioTools Inc. (NASDAQ: LAB) wird die Finanzzahlen für das vierte Quartal und das Gesamtjahr 2025 am Dienstag, den 24. Februar 2026, nach Börsenschluss in den USA veröffentlichen. Die Ergebnisse werden auf de
02-10 20:01
Standard BioTools to Announce Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
Standard BioTools Inc. (NASDAQ: LAB) announced it will release its fourth-quarter and full-year 2025 financial results on February 24, 2026, after U.S. market close. The company specializes in providing standardized next-generation technologies for biomedical research, helping to accelerate the development of better medicines. Its proprietary mass cytometry and microfluidics technologies enable reliable insights for translational and clinical res...
02-10 12:00
Standard BioTools veröffentlicht ergänzte Finanzinformationen nach Verkauf der SomaScan-Sparte
Standard BioTools veröffentlicht ergänzte Finanzinformationen nach Verkauf der SomaScan-Sparte Standard BioTools Inc. hat eine Ergänzung zu einem aktuellen Bericht (Form 8-K/A) veröffentlicht. Das Unternehmen informiert darin über den Abschluss des Verkaufs sämtlicher Anteile an SomaLogic, Inc. sowi
02-06 05:39
Standard BioTools Completes Sale Of SomaLogic To Illumina For Up To $425M Plus Royalties
Received $350 Million in upfront cash at closing; Up to $425 Million in total proceeds inclusive of near-term earnout paymentsApproximately $550 Million in cash & cash equivalents on balance sheet at close, excluding
01-30 22:14
Standard BioTools Completes Sale of SomaLogic to Illumina
Standard BioTools completed the sale of SomaLogic to Illumina for $350 million upfront, plus up to $75 million in earnouts and royalties. The transaction enhances the company's financial position, with $550 million in cash to fuel M&A growth. CEO Michael Egholm highlighted the strategic transformation and strengthened financial standing. The deal includes IP licenses and royalty streams, positioning the company for future expansion.
01-30 14:09
Neogen Posts Strong Q2 Earnings, Joins Astronics, Lockheed Martin, Constellation Brands And Other Big Stocks Moving Higher On Thursday
U.S. stocks were mixed, with the Dow Jones index gaining around 100 points on T...
01-08 23:20
Standard BioTools Reports $56M Q4 Preliminary Revenue And $185M In FY2025 Preliminary Revenue
Standard BioTools Inc. (NASDAQ:LAB) ("Standard BioTools" or the "Company") today announced preliminary and unaudited revenue results for the fourth quarter and full year 2025. Standard BioTools expects fourth quarter
01-08 20:18
